Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Journal of hepatocellular carcinoma（2023）
Abstract
Compared to regorafenib plus ICIs, regorafenib plus ICIs with TACE was tolerated and improved survival as the second-line treatment for patients with advanced HCC.
MoreTranslated text
Key words
advanced hepatocellular carcinoma,immune checkpoint inhibitors,regorafenib,second-line treatment,transarterial chemoembolization
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined